Xlife Sciences : Praesentation

THE LE ADI NG E UROPE AN LI FE S CI ENCES I NCUBATOR AND ACCELE RATOR

Disclaimer

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION WOULD BE UNLAWFUL

The presentation has been prepared by Xlife Sciences Ltd. ("Xlife", and together with its subsidiaries, the "Xlife Group") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority.

The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe

for or purchase any loans or securities of or make an investment in Xlife or any other member of the Xlife Group or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision.

No representation, warranty or undertaking, express or implied, is made by Xlife or any member of the Xlife Group or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained therein or any other statement made or purported to be made in connection with Xlife, the Xlife Group or any member thereof, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Xlife or any member of the Xlife Group or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Xlife's forward-looking statements prove to be incorrect, the actual results may be materially different from those Xlife expresses or implies by such statements. Xlife does not intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of their publication.

The securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended) and Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018.

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	1

COMPANY OVERVIEW

Xlife Sciences is a Swiss life sciences incubator and accelerator.

2019	1	~5.70 M	49.9%
LAUNCH	STOCK EXCHANGE	SHARES	FREE FLOAT
WITH 6 PROJECT COMPANIES	SPARKS SEGMENT SIX SWISS EXCHANGE	5.703.292 SHARES WITH A NOMINAL	43.0% FOUNDERS, 7.1% MANAGEMENT
	SINCE FEBRUARY 2022,	VALUE OF CHF 1
	PREVIOUS MUNICH STOCK EXCHANGE

~200 M	>40/100k	24/4/34	>15
MARKET CAPITALIZATION	INNOVATION PARTNERS	PORTFOLIO COMPANIES	EMPLOYEES
May 2024	WITH UNIVERSITIES, RESARCH INSTITUTIONS &	IN 4 INVESTMENT PILLARS	XLIFE SCIENCES AG /
	INDUSTRY PARTNERS / ACCESS TO SCIENTISTS	WITH 36 PROJECTS	PROJECT COMPANIES

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	2

BUSINESS MODEL

Xlife Sciences supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

~300	~3-5	~1.5 M	~500k
INVENTION DISCLOSURES P.A.	NEW PROJECT COMPANIES P.A.	FINANCING	POTENTIAL GRANTS

WHERE WE ADD VALUE TO OUR PROJECT COMPANIES

BREAKDOWN BY PROJECT DEVELOPMENT PHASE

EXIT STRATEGIES

PROOF OF CONCEPT

HR

M&A

STRUCTURING

MARKETING

BUSINESS

DEVELOPMENT

LICENSE DEAL

TRADE SALE

RESEARCH

PATENTING

LICENSING

IPO

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	3

INVESTMENT PROCESS

	3	4
2	EXIT
	STRATEGY
ACTIVE MANAGEMENT &

1	SYNERGIES
BUSINESS EVALUATION &
	SCIENTIFIC ASSESSMENT

INITIAL CONTACT &

INVENTION DISCLOSURE

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	4

COMPANY LEADERSHIP

MANAGEMENT

BOARD OF DIRECTORS

ADVISORY BOARD

Oliver R. Baumann	Carl von Halem	Dr. Frank Plöger	Christian Faber
Chief Executive Officer	Chief Financial Officer	Chief Scientific Officer	Head of Legal &
			Compliance

David L. Deck	Désirée Dosch	Dr. Norbert Windhab	Mark S. Müller
President of the Board	Member of the Board	Member of the Board	Member of the Board
of Directors	of Directors	of Directors	of Directors

Prof. Dr. habil.	Prof. Dr. Ernst	Prof. Dr. Hans-Georg	Prof. Dr. Johannes
Michael B. Klein	Rietschel	Rammensee	Schumacher
Politics Expert	Immunology Expert	Immunology Expert	Human Genetics Expert

Dr. med. Uwe Rudolf	Dr. med. Ralf	Dr. Bernward	Prof. Dr.
Max Reuter, DM	Oettmeier	Garthoff	Jürgen Eckel
Head Physician at	Head Physician at	Industry Expert	Diabetes Expert
Klinik Im Leben	Alpstein Clinic

Beat Kläui

Head of Accounting and Taxes

Oliver R. Baumann

Member of the Board

of Directors

Dr. Christoph

Brücher

Industry Expert

Prof. Dr.

Ulrich Räth

Industry Expert

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	5

KEY FOCUS AREAS & PROJECT COMPANIES

TECHNOLOGY PLATFORMS

BIOTECH & THERAPIES

®

MEDICAL TECHNOLOGY

ARTIFICIAL INTELIGENCE

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	6

SELECTED MARKETS

	ONCOLOGY			METABOLIC /
			INFLAMMATION

MEDICAL DEVICES		3D-PRINTING		DIAGNOSTICS		OBESITY

CRO

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]	7

PORTFOLIO

Our approach is to be in the driver seat. In over 50% of the new project companies, Xlife Sciences initiated the spin-off process directly from and with a university or research institution.

INITIAL PROJECTS #4 (2)

SPIN-OFF #12

STRATEGIC #5 (1)

INDUSTRY JOINT VENTURE #3

25%	14%	51%	100%	75%	License	50%	50%
							®
17%	5%	67%	100%	50%	20%	40%

70%	19%	35%
						JOINT VENTURE PARTNER
100%	70%
				50%	50%
EXITED		EXITED
		46%	100%
				60%
100%	100%
Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]						8

PROJECT STAGE

T E C H N O L O G Y P L A T F O R M S			A R T I F I C I A L I N T E L L I G E N C E
XLIFE	R&D	POC	EXIT	XLIFE	R&D	POC	EXIT
				2023
2019				M E D I C A L T E C H N O L O G Y & D I A G N O S T I C S
B I O T E C H N O L O G Y & T H E R A P I E S			XLIFE	R&D	POC	EXIT
XLIFE	R&D	POC	EXIT
2019
2021
2021
2019
2020
2021				®
2019
2020
2022
2023

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.	.ch	9